Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Breast Cancer

Breast Cancer

23 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Breast Cancer

1185 trials tracked for Breast Cancer: 221 in phase 3 or 4 and 97 with published results. The most-cited published study has 2600 citations.

1,185Trials tracked
221Phase 3 & 4
0Recruiting
97With published results
Phase distribution
Phase 4 32 Phase 3 189 Phase 2 548 Phase 1 87 Other / NA 329
  1. Phase 3 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Completed · 2,600 cited
  2. Phase 3 A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) Completed · 2,143 cited
  3. Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,650 cited
  4. Phase 3 Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer Completed · 1,511 cited
  5. Phase 3 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer Completed · 1,078 cited
  6. Phase 3 Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid Completed · 1,020 cited
Show 44 more trials
  1. Phase 3 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Completed · 746 cited
  2. Phase 3 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Completed · 727 cited
  3. Phase 3 Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors Completed · 714 cited
  4. Phase 3 Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Completed · 687 cited
  5. Phase 3 Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients Completed · 684 cited
  6. Phase 3 S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Completed · 645 cited
  7. Phase 3 Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy Completed · 645 cited
  8. Phase 3 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Completed · 596 cited
  9. Phase 3 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Completed · 557 cited
  10. Phase 3 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed · 540 cited
  11. Phase 3 Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Completed · 539 cited
  12. Phase 3 Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer Completed · 491 cited
  13. Phase 3 Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation Completed · 463 cited
  14. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 417 cited
  15. Phase 3 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer Completed · 413 cited
  16. Phase 3 Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer Completed · 378 cited
  17. Phase 3 S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Completed · 374 cited
  18. Phase 3 A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer Completed · 345 cited
  19. Phase 3 A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment Completed · 342 cited
  20. Phase 3 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Completed · 338 cited
  21. Phase 3 A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery Completed · 322 cited
  22. Phase 3 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Completed · 320 cited
  23. Phase 3 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Completed · 304 cited
  24. Phase 3 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Completed · 222 cited
  25. Phase 3 S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo Completed · 213 cited
  26. Phase 3 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed · 205 cited
  27. Phase 3 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed · 195 cited
  28. Phase 3 Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel Completed · 191 cited
  29. Phase 3 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Completed · 166 cited
  30. Phase 3 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Completed · 164 cited
  31. Phase 3 Secondary Adjuvant Long Term Study With Arimidex Completed · 159 cited
  32. Phase 3 Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) Completed · 149 cited
  33. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 143 cited
  34. Phase 3 Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. Completed · 143 cited
  35. Phase 3 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women Completed · 133 cited
  36. Phase 3 Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors Completed · 132 cited
  37. Phase 3 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Completed · 129 cited
  38. Phase 3 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer Completed · 122 cited
  39. Phase 4 Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer Completed · 117 cited
  40. Phase 3 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Completed · 117 cited
  41. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
  42. Phase 3 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed · 101 cited
  43. Phase 3 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer Completed · 98 cited
  44. Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Completed · 93 cited

Showing the 50 most-cited and recently-updated of 1,185 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer
Oncology Phase II
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer New Drug Combo Helps Breast Cancer After CDK4/6 Failure
This phase 2 trial evaluated tucidinostat plus metronomic capecitabine with endocrine therapy in 66 patients with HR-positive HER2-negative …
A new drug mix shrinks tumors in advanced breast cancer patients whose disease grew after standard treatments failed.
Apr 17, 2026
IC-ECG-guided port placement in three breast cancer patients with PLSVC showed no complications
Cardiology Sys. Review
IC-ECG-guided port placement in three breast cancer patients with PLSVC showed no complications When Your Chest Port Takes an Unexpected Route to Your Heart
This case series and literature review examined implantable venous access port placement in three breast cancer patients with persistent lef…
A small signal on the heart monitor during port placement can reveal a harmless but important difference in how some people's blood returns …
Frontiers Apr 13, 2026
Digital and AI-supported psychosocial interventions modestly reduce distress and improve quality of life in women with breast cancer
Oncology Meta-analysis
Digital and AI-supported psychosocial interventions modestly reduce distress and improve quality of life in women with breast cancer Digital mental health tools may help breast cancer patients feel better
This systematic review and meta-analysis of randomized controlled trials evaluated digital and AI-supported psychosocial interventions in wo…
Digital mental health tools using AI and mindfulness help breast cancer patients reduce stress, anxiety, and depression while improving dail…
Apr 9, 2026
Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
Oncology Meta-analysis
Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles New analysis suggests specific chemo schedules may improve outcomes for early breast cancer patients
This network meta-analysis evaluated Phase II and Phase III trials involving 17,187 women with early-stage breast cancer receiving adjuvant…
A new analysis of 17,187 women with early breast cancer suggests specific chemo schedules may improve outcomes and reduce side effects.
Apr 9, 2026
Axillary ultrasound did not improve sentinel lymph node detection rates compared to clinical examination alone in early-stage breast cancer patients
OB/GYN & Women's Health RCT
Axillary ultrasound did not improve sentinel lymph node detection rates compared to clinical examination alone in early-stage breast cancer patients Ultrasound scans did not change breast cancer surgery outcomes in this large study
This Phase III randomized controlled trial analyzed data from 4,806 patients with early-stage breast cancer across 34 European sites.
Ultrasound scans did not change breast cancer surgery outcomes in this large study of 4,806 patients across 34 European sites.
Apr 9, 2026
Meta-analysis finds [68Ga]Ga-FAPI PET shows high diagnostic accuracy for gynecologic cancers
Oncology Meta-analysis
Meta-analysis finds [68Ga]Ga-FAPI PET shows high diagnostic accuracy for gynecologic cancers Could a new scan spot breast and ovarian cancer tumors better than the standard test?
A meta-analysis of 253 females with breast, ovarian, and cervical cancers compared [68Ga]Ga-FAPI PET to [18F]F-FDG PET imaging.
A new scan using a different tracer finds breast, ovarian, and cervical cancer tumors and spread much better than the standard test doctors …
Apr 9, 2026
Meta-analysis finds BMI affects pCR rates in breast cancer patients receiving neoadjuvant chemotherapy
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds BMI affects pCR rates in breast cancer patients receiving neoadjuvant chemotherapy Body weight may affect breast cancer treatment response, large analysis suggests
A systematic review and meta-analysis of 15,235 breast cancer patients undergoing neoadjuvant chemotherapy found that overweight or obese pa…
Overweight or obese women with breast cancer are less likely to achieve a complete response to chemotherapy before surgery, a large analysis…
Apr 6, 2026
NAUTILUS RCT reports 11.2% ALN metastasis rate in SLNB arm for cT1-2/N0 breast cancer
OB/GYN & Women's Health RCT
NAUTILUS RCT reports 11.2% ALN metastasis rate in SLNB arm for cT1-2/N0 breast cancer Study details baseline characteristics in breast cancer trial testing lymph node biopsy omission
This randomized controlled trial of 1,734 cT1-2/N0 breast cancer patients reports baseline characteristics and axillary lymph node status.
Patients with early-stage breast cancer and small tumors might skip a painful arm surgery if their cancer hasn't spread, based on new trial …
Apr 6, 2026
Hypofractionated stereotactic radiation therapy showed high local control in breast cancer brain metastases
OB/GYN & Women's Health Phase II
Hypofractionated stereotactic radiation therapy showed high local control in breast cancer brain metastases FSRT shows promising results for brain metastases in breast cancer patients
This prospective single-arm phase 2 trial evaluated fractionated stereotactic radiation therapy (FSRT) in 173 patients with breast cancer an…
Fractionated stereotactic radiation therapy kept brain cancer controlled in 88.6% of breast cancer patients after one year with no severe si…
Apr 6, 2026
DIBH reduces radiation dose to heart and lungs in left-sided breast cancer VMAT
Oncology Meta-analysis
DIBH reduces radiation dose to heart and lungs in left-sided breast cancer VMAT Breath-hold technique reduces radiation dose to heart during breast cancer treatment
A meta-analysis of 11 studies in left-sided breast cancer patients treated with VMAT found deep inspiration breath hold (DIBH) reduced mean …
Holding a deep breath during radiation therapy consistently lowers the dose to the heart, lungs, and other organs for left-sided breast canc…
Apr 6, 2026
Single-fraction stereotactic partial breast irradiation shows promising early control in early-stage breast cancer
OB/GYN & Women's Health Phase II
Single-fraction stereotactic partial breast irradiation shows promising early control in early-stage breast cancer Can a single radiation dose protect women after breast cancer surgery?
A prospective single-institution phase 2 trial of 148 patients with early-stage breast cancer after breast-conserving surgery found single-f…
A single radiation dose for breast cancer recovery showed low recurrence and mild side effects in early results from a new treatment approac…
Apr 4, 2026

Questions about Breast Cancer

Is there any research on using AI for Breast Cancer pathology?

Yes, AI is being researched for breast cancer pathology, including digital pathology, deep learning for imaging, and machine learning for biomarker detection.

Full answer →
Can a plasma lipid panel help detect early stage Breast Cancer?

Yes, early research shows plasma lipid panels can help detect early-stage breast cancer, with machine learning models achieving high accuracy, but they are not yet standard clinical tests.

Full answer →
What are the new treatments for triple-negative and HER2-positive Breast Cancer?

New treatments for triple-negative breast cancer include chemo-immunotherapy (pembrolizumab plus platinum-based chemo) and potential NY-ESO-1 targeted therapies; for HER2-positive breast cancer, neoadjuvant targeted combinations and post-neoadjuvant trastuzumab emtansine are key

Full answer →
Does the PECS II block reduce morphine use after Breast Cancer surgery?

Yes, the PECS II block significantly reduces morphine use after breast cancer surgery, based on multiple randomized trials and a meta-analysis.

Full answer →
Can deep learning help doctors find Breast Cancer on tomosynthesis scans?

Yes, deep learning can help doctors find breast cancer on tomosynthesis scans, matching or improving radiologist accuracy in some cases.

Full answer →
See all 5 questions about Breast Cancer →